secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0000899923-25-000010
Event type: leadership
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics: CEO succession plan; Q4 revenue $211M (+7%), FY 2024 revenue $838M (+11%)
--------------------------------------------------------------------------------

- CEO Paul J. Diaz resigns effective April 30, 2025; COO Samraat S. Raha appointed President, CEO, and Board member.
- Mark S. Verratti promoted to COO effective April 30, succeeding Raha.
- Q4 2024 revenue $211M (+7% YoY); full-year revenue $838M (+11% YoY). GAAP net loss $43M (Q4) and $127M (FY).
- Adjusted EBITDA Q4 $11M, FY $40M; 2025 guidance reaffirmed: revenue $840-$860M, adjusted EPS $0.07-$0.11.
- Exclusive license of PATHOMIQ AI platform for prostate cancer; commercial launch planned later in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992325000010/0000899923-25-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992325000010/mygn-20250224.htm
  HTML page:      https://secwatch.observer/filing/0000899923-25-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer